Vaishali Pharma Limited (NSE:VAISHALI)

Market Cap	931.50M -41.1%
Revenue (ttm)	1.13B +13.7%
Net Income	41.65M +409.5%
EPS	0.32 +433.3%
Shares Out	130.46M
PE Ratio	22.31
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	131,632
Open	7.12
Previous Close	7.18
Day's Range	7.03 - 7.31
52-Week Range	4.75 - 13.59
Beta	0.38
Analysts	n/a
Price Target	n/a
Earnings Date	May 30, 2026

About Vaishali Pharma

Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti–malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic. The company also provides...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 27
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: VAISHALI

Financial Performance

In fiscal year 2026, Vaishali Pharma's revenue was 1.13 billion, an increase of 13.72% compared to the previous year's 990.26 million. Earnings were 41.65 million, an increase of 409.52%.